Paper Details

  1. Home
  2. Paper Details

Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.

Author: AdamsAshok, Allen-PhilbeyKimberley, BakerDavid, CampionTom, De TraneStefania, EspasandinMaria, GiovannoniGavin, GnanapavanSharmilee, MaoZhifeng, MartaMonica, MathewsJoela, SchmiererKlaus, TurnerBenjamin P, YildizOzlem, Álvarez-GonzálezCésar

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Cladribine, a medication for multiple sclerosis, was withdrawn from the market in 2011 due to lymphopenia. This study investigated the real-life safety and tolerability of subcutaneously injected cladribine.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND" NlmCategory="BACKGROUND">Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with progressive MS (pwPMS). Cladribine has shown ef...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.msard.2018.11.001

データ提供：米国国立医学図書館（NLM）

Treating the Ineligible: Disease Modification in Multiple Sclerosis

In the ever-shifting sands of multiple sclerosis (MS) research, scientists are constantly seeking new strategies to combat this complex and often debilitating disease. This study addresses the challenges of accessing disease-modifying treatments (DMTs) for individuals with progressive MS (pwPMS), a condition that can feel like navigating a vast and unforgiving desert.

Cladribine: A Potential Oasis in the Desert of MS

The study highlights the potential of cladribine, a drug that has shown efficacy at all stages of MS. Although previously withdrawn from the market due to concerns related to lymphopenia, the authors report on the real-life safety and tolerability of subcutaneously injected cladribine in treating both pwRMS and pwPMS. This research offers a glimmer of hope for individuals with progressive MS, potentially providing a path toward more effective treatment options.

Navigating the Challenges of Access and Treatment: A Journey Through the MS Landscape

The study emphasizes the need for addressing the barriers to accessing DMTs, particularly for those with pwPMS. The authors call for a more equitable approach to treatment, ensuring that all individuals with MS have access to effective therapies.

Health Implications and Lifestyle Applications: Embracing Hope and Advocacy

This research underscores the ongoing struggle for individuals with MS to access appropriate treatments. It highlights the importance of advocacy and research efforts to expand access to DMTs for all individuals, regardless of disease stage.

Dr. Camel's Conclusion

This study reminds us that the journey through the desert of MS is often challenging, but hope can be found in the form of new research and treatment options. The authors emphasize the importance of advocating for increased access to DMTs, ensuring that all individuals with MS can benefit from the potential of these life-changing therapies.
Date :
  1. Date Completed 2019-04-16
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

30419510

DOI: Digital Object Identifier

10.1016/j.msard.2018.11.001

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.